Condition

Ductal Carcinoma In Situ, DCIS

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting3

Common interventions6

Lead sponsors shown3

Clinical trials

4 shown

Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryNCT07762924 · 2026-09-01

RECRUITING

Personalized Prone Immobilization for Accelerated Partial Breast RadiotherapyNCT07711847 · 2026-07-02

RECRUITING

Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving SurgeryNCT07762885 · 2026-07-01

RECRUITING

Areola Preservation in NSM With Nipple InvolvementNCT07544134 · 2026-05-01

NOT_YET_RECRUITING

Common interventions

Adjuvant RadiotherapyRADIATION1 Areola-Preserving Nipple-Sparing Mastectomy with Immediate Nipple ReconstructionPROCEDURE1 Endocrine Therapy (Optional)DRUG1 ObservationOTHER1 tamoxifenDRUG1 VENUS SHELL™ immobilization deviceDEVICE1

Leading sponsors

Fudan University 2 HeroSupport SA 1 Second Affiliated Hospital, Zhejiang University, School of Medicine 1

Trial status mix

RECRUITING3

NOT_YET_RECRUITING1

Phase mix

NA2

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.